

# PARTNERSHIP HEALTHPLAN OF CALIFORNIA

## POLICY/ PROCEDURE

<b>Policy/Procedure Number:</b> MPUP3144 (previously MCUP3144, MCCP2028)			<b>Lead Department:</b> Health Services <b>Business Unit:</b> Utilization Management	
<b>Policy/Procedure Title:</b> Residential Substance Use Disorder Treatment Authorization			<input checked="" type="checkbox"/> <b>External Policy</b> <input type="checkbox"/> <b>Internal Policy</b>	
<b>Original Date:</b> 11/13/2019 (MCCP2028) <b>Effective Date:</b> 07/01/2020 (MCCP2028)		<b>Next Review Date:</b> 06/11/2026 <b>Last Review Date:</b> 06/11/2025		
<b>Applies to:</b>	<input type="checkbox"/> <b>Employees</b>	<input checked="" type="checkbox"/> <b>Medi-Cal</b>	<input checked="" type="checkbox"/> <b>Partnership Advantage</b>	
<b>Reviewing Entities:</b>	<input checked="" type="checkbox"/> <b>IQI</b>	<input type="checkbox"/> <b>P &amp; T</b>	<input checked="" type="checkbox"/> <b>QUAC</b>	
	<input type="checkbox"/> <b>OPERATIONS</b>	<input type="checkbox"/> <b>EXECUTIVE</b>	<input type="checkbox"/> <b>COMPLIANCE</b>	<input type="checkbox"/> <b>DEPARTMENT</b>
<b>Approving Entities:</b>	<input type="checkbox"/> <b>BOARD</b>		<input type="checkbox"/> <b>COMPLIANCE</b>	<input type="checkbox"/> <b>FINANCE</b>
	<input type="checkbox"/> <b>CEO</b>	<input type="checkbox"/> <b>COO</b>	<input type="checkbox"/> <b>CREDENTIALING</b>	<input checked="" type="checkbox"/> <b>PAC</b>
<b>Approval Signature:</b> Robert Moore, MD, MPH, MBA			<b>Approval Date:</b> 06/11/2025	

### I. RELATED POLICIES:

- A. MCCP2022 – Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) Services
- B. MCUP3037 – Appeals of Utilization Management/Pharmacy Decisions
- C. MPUD3001 – Utilization Management Program Description
- D. CGA024 – Medi-Cal Member Grievance System
- E. MPQP1016 – Potential Quality Issue Investigation and Resolution
- F. MCUP3113 – Telehealth Services
- G. CMP41 – Wellness and Recovery Records

### II. IMPACTED DEPTS:

- A. Administration
- B. Behavioral Health
- C. Claims
- D. Health Services
- E. Member Services
- F. Provider Relations

### III. DEFINITIONS

- A. American Society of Addiction Medicine (ASAM) Criteria - As defined in the Department of Health Care Services (DHCS) Drug Medi-Cal Organized Delivery System Intergovernmental Agreement, pertains to necessary care for biopsychosocial severity and is defined by the extent and severity of problems in all six multidimensional assessment areas of the patient. Currently using ASAM Criteria 3<sup>rd</sup> Edition.
- B. Discharge – The process to prepare the program beneficiary for referral into another level of care, post treatment return or re-entry into the community, and/or the linkage of the individual to essential community treatment, housing, and human services.
- C. Behavioral Health Clinical Director – The Partnership HealthPlan of California (Partnership) Behavioral Health Clinical Director is a Doctor of Medicine (MD), Doctor of Osteopathic Medicine (DO), clinical Doctor of Philosophy (PhD), or Doctor of Psychology (PsyD) who is actively involved in the behavioral health aspects of Partnership activities. This Director provides clinical oversight of Partnership's behavioral health activities including substance use services and the activities of Partnership's delegated managed behavioral health organization(s). The Behavioral Health Clinical Director has the authority to make decisions based on medical necessity which result in the approval or denial of coverage for behavioral health or substance use disorder treatment related services.

<b>Policy/Procedure Number: MPUP3144 (previously MCUP3144, MCCP2028)</b>		<b>Lead Department: Health Services Business Unit: Utilization Management</b>	
<b>Policy/Procedure Title:</b> Residential Substance Use Disorder Treatment Authorization		<input checked="" type="checkbox"/> <b>External Policy</b> <input type="checkbox"/> <b>Internal Policy</b>	
<b>Original Date:</b> 11/13/2019 (MCCP2028) <b>Effective Date:</b> 07/01/2020 (MCCP2028)		<b>Next Review Date:</b> 06/11/2026 <b>Last Review Date:</b> 06/11/2025	
<b>Applies to:</b>	<input type="checkbox"/> <b>Employees</b>	<input checked="" type="checkbox"/> <b>Medi-Cal</b>	<input checked="" type="checkbox"/> <b>Partnership Advantage</b>

- D. Licensed Practitioner of the Healing Arts (LPHA): Physicians, Nurse Practitioners, Physician Assistants, Registered Nurses, Registered Pharmacist, Licensed Clinical Psychologist, Licensed Clinical Social Worker (LCSW), Licensed Professional Clinical Counselor, Licensed Marriage and Family Therapist (LMFT), and licensed-eligible practitioners working under the supervision of licensed clinicians.
- E. Medical Necessity – Medical Necessity means those treatment services that are reasonable and necessary to protect life, prevent significant illness or significant disability, or alleviate severe pain through the diagnosis or treatment of disease, illness or injury consistent with Title 42 Code of Federal Regulations (CFR) 438.210 (a) (4).
- F. Medical Necessity for Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) Services: (California refers to the EPSDT benefit as *Medi-Cal for Kids & Teens*.) For individuals under 21 years of age, a service is medically necessary if the service meets the standards set for in Section 1396d(r)(5) of Title 42 of the United States Code and is necessary to correct or ameliorate defects and physical and mental illnesses that are discovered by screening services
- G. Non-Urgent Request – A request for medical care or services for which application of the time periods for making a decision does not jeopardize the life or health of the Member or the Member’s ability to regain maximum function and would not subject the Member to severe pain.
- H. Partnership Advantage: Effective January 1, 2026, Partnership HealthPlan of California will operate a Centers for Medicare & Medicaid Services (CMS)-approved Dual-Eligible Special Needs Plan (D-SNP) in specific counties as described in the Department of Health Care Services (DHCS) CalAIM Dual Eligible Special Needs Plan Policy Guide. This line of business will be known as Partnership Advantage and will be a Medicare Advantage plan offered to all full-benefit, dual-eligible beneficiaries 21 years of age or older who reside in the applicable counties. Partnership Advantage Members will be qualified to receive both Medi-Cal and Medicare services as described in the Partnership Advantage Member Handbook.
- I. Program Beneficiary – A person who: (1) has been determined eligible for full scope Medi-Cal; (2) is not institutionalized; (3) meets criteria for authorization as described in section VI. A. below; (4) meets the admission criteria to receive Drug Medi-Cal (DMC) covered services; and (5) resides in Humboldt, Lassen, Mendocino, Modoc, Shasta, Siskiyou, or Solano County.
- J. Residential Treatment – As defined for DMC purposes, Residential Treatment means a non-institutional, 24-hour non-medical, short-term residential program of any size that provides rehabilitation services to beneficiaries. Each program beneficiary shall live on the premises and shall be supported in their efforts to restore, maintain, and apply interpersonal and independent living skills and access community support systems. Programs shall provide a range of activities and services. Residential treatment shall include 24-hour structure with available trained personnel, seven days a week, including a minimum of five hours of clinical service a week to prepare beneficiary for outpatient treatment.
- K. Urgent Request – A request for medical care or services where application of the timeframe for making routine or non-life threatening care determinations:
  - 1. Could seriously jeopardize the life, health or safety of the Member or others, due to the Member’s psychological state, or
  - 2. In the opinion of a practitioner with knowledge of the Member’s medical or behavioral condition, would subject the Member to adverse health consequences without the care or treatment that is the subject of the request.

#### IV. ATTACHMENTS:

A. N/A

#### V. PURPOSE:

The purpose of this policy is to describe the procedures used by Partnership HealthPlan of California (Partnership) to process Treatment Authorization Requests (TARs) for residential substance use disorder treatment services.

<b>Policy/Procedure Number: MPUP3144 (previously MCUP3144, MCCP2028)</b>		<b>Lead Department: Health Services Business Unit: Utilization Management</b>	
<b>Policy/Procedure Title:</b> Residential Substance Use Disorder Treatment Authorization		<input checked="" type="checkbox"/> <b>External Policy</b> <input type="checkbox"/> <b>Internal Policy</b>	
<b>Original Date:</b> 11/13/2019 (MCCP2028) <b>Effective Date:</b> 07/01/2020 (MCCP2028)		<b>Next Review Date:</b> 06/11/2026 <b>Last Review Date:</b> 06/11/2025	
<b>Applies to:</b>	<input type="checkbox"/> <b>Employees</b>	<input checked="" type="checkbox"/> <b>Medi-Cal</b>	<input checked="" type="checkbox"/> <b>Partnership Advantage</b>

## VI. POLICY / PROCEDURE:

### A. Criteria for Authorization of Residential Treatment Services for Substance Use Disorders (SUD)

1. Partnership HealthPlan of California (Partnership) authorizes residential treatment services for substance use disorders according to the specific terms of the contract with the provider and in accordance with the medical necessity requirements specified in Title 22, Section 51303 and the coverage provisions of the approved State Medi-Cal Plan for Medi-Cal eligible beneficiaries as described below:
  - a. Adults (Age 21 or older)
    - 1) Must have at least one diagnosis from the Diagnostic and Statistical Manual of Mental Disorders (DSM) for Substance-Related and Addictive Disorders (with the exception of Tobacco Related Disorders and Non-Substance Related Disorders).
    - 2) Must meet the ASAM criteria definition of medical necessity for services based on the ASAM Criteria, 3<sup>rd</sup> Edition. An LPHA at the residential facility (provider) will assess the Medi-Cal eligible beneficiary using a multi-dimensional assessment based on the ASAM criteria. A summary of the assessment findings must be submitted with the Treatment Authorization Request (TAR) to Partnership.
  - b. Adolescents up to the twenty-first [21<sup>st</sup>] birthday
    - 1) These Medi-Cal eligible beneficiaries are also eligible to receive Medicaid services under the Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) program. Under the EPSDT mandate, they are eligible to receive all appropriate and medically necessary services needed to correct and ameliorate health conditions that are coverable under section 1905(a) Medicaid authority.
    - 2) Must meet the ASAM criteria definition of medical necessity for services based on the ASAM adolescent criteria. An LPHA at the residential facility (provider) will assess the Medi-Cal eligible beneficiary using a multi-dimensional assessment based on the ASAM adolescent criteria. A summary of the assessment findings must be submitted with the TAR to Partnership.
  - c. Program beneficiaries (as defined in III.I.) who are also Partnership Advantage Members (as defined in III.H), are eligible for residential SUD treatment under their Medi-Cal benefit as described in this policy.
2. Partnership utilizes InterQual® Behavioral Health Criteria to ensure that the services are medically necessary and provided in sufficient amount, duration, or scope to reasonably achieve the purpose for which the services are furnished.
3. Partnership shall not arbitrarily deny or reduce the amount, duration, or scope of a medically necessary service solely because of the diagnosis, type of illness, or condition of the beneficiary. This does not exclude use of industry standard utilization management practices.

### B. Initial Authorization Process Overview

1. When the Medi-Cal eligible beneficiary presents to the residential substance use disorder treatment facility (provider), an LPHA will conduct an assessment to determine if the Medi-Cal eligible beneficiary meets medical necessity criteria for admission.
2. Within one business day of the intake, the residential provider shall submit a TAR with a summary of the assessment findings and a treatment plan to the Partnership Health Services Department for review.
  - a. TAR determinations cannot be made by Partnership until all required documents and information are received.
  - b. TARs should be submitted electronically via Partnership's Online Services portal as electronic submission will allow for more expedient processing. If online submission is not possible, the TAR may be submitted via fax number (707) 863-4118 to Partnership's Health Services Department for review.

<b>Policy/Procedure Number: MPUP3144 (previously MCUP3144, MCCP2028)</b>		<b>Lead Department: Health Services Business Unit: Utilization Management</b>	
<b>Policy/Procedure Title:</b> Residential Substance Use Disorder Treatment Authorization		<input checked="" type="checkbox"/> <b>External Policy</b> <input type="checkbox"/> <b>Internal Policy</b>	
<b>Original Date:</b> 11/13/2019 (MCCP2028) <b>Effective Date:</b> 07/01/2020 (MCCP2028)		<b>Next Review Date:</b> 06/11/2026 <b>Last Review Date:</b> 06/11/2025	
<b>Applies to:</b>	<input type="checkbox"/> <b>Employees</b>	<input checked="" type="checkbox"/> <b>Medi-Cal</b>	<input checked="" type="checkbox"/> <b>Partnership Advantage</b>

3. Partnership's Utilization Management (UM) staff reviews the documentation submitted with the TAR using the non-urgent preservice review time frame and notifies the provider of the determination within 5 business days of receipt of the request.
    - a. Partnership's UM staff includes nurse coordinators who are Registered Nurses (RNs) with specialized ASAM training who can approve and defer (pend) the TAR, or deny the TAR for administrative reasons (e.g. TAR not required, duplicate request, or invalid code). Any decision requiring medical necessity determination will be referred to a Physician as per 3.b. below. The nurse coordinator reviews the information received from the residential treatment provider utilizing the approved review guidelines as described in section VI.A. above.
    - b. Requests that do not meet review guidelines are referred to the Behavioral Health Clinical Director (described in section III.C. above) or Physician Designee for further evaluation. When a TAR requires clinician review, the nurse coordinator attaches all relevant documentation, InterQual® criteria and the Medical Director Worksheet.
    - c. Notification of approved TARs will be provided to the provider at the time of decision, but no later than 24 hours from the date of decision.
  4. A TAR submission may be initially approved from date of intake up to 30 days for adults and up to 15 days for adolescents.
- C. Continued Stay/Reauthorization Process
1. Partnership will review the program beneficiary's progress periodically throughout their length of stay as appropriate.
  2. The provider submits a summary of the updated assessment findings, an updated treatment plan and a TAR or discharge plan to Partnership no later than five business days prior to the expiration of the previous authorization.
    - a. Continued stay residential SUD treatment authorizations do not meet the definition of "urgent care." These requests are classified as non-urgent preservice review, and Partnership will review and notify the provider of the determination (approved, modified, deferred/pended, or denied) within 5 business days of receipt of the request.
  2. Adults (Age 21 or older)
    - a. The duration of stay in a residential treatment center is not expected to exceed 90 days. Any length of stay beyond 90 days requires prior approval from Partnership.
    - b. After completing 90 days of treatment, Partnership may approve extensions of the stay based upon medical necessity and the treatment plan.
  3. Adolescents up to the twenty-first [21<sup>st</sup>] birthday
    - a. Adolescent beneficiaries receiving residential treatment shall be stabilized as soon as possible and moved down to a less intensive level of treatment.
    - b. EPSDT beneficiaries may receive a longer length of stay based on medical necessity.
  4. Pregnant/Post-Partum Beneficiaries
    - a. Pregnant beneficiaries may receive residential treatment services during pregnancy and up to 60 days during the post-partum period (which begins on the last day of pregnancy). Extension beyond 60 days will require prior approval from Partnership and must be to a non-perinatal level of care.
    - b. Providers will be required to provide proof of pregnancy or delivery date for each new TAR submitted to Partnership.
- D. Notification of Denials/Modifications/Appeals Process
1. Only the Behavioral Health Clinical Director or Physician Designee can deny for reasons of medical necessity.
  2. For any decision to deny a TAR or to authorize a service in an amount, duration, or scope that is less than requested, electronic or written notification of the decision and how to initiate an appeal, if applicable, is communicated to the provider within 24 hours of the decision and written notification

<b>Policy/Procedure Number: MPUP3144 (previously MCUP3144, MCCP2028)</b>		<b>Lead Department: Health Services Business Unit: Utilization Management</b>	
<b>Policy/Procedure Title:</b> Residential Substance Use Disorder Treatment Authorization		<input checked="" type="checkbox"/> <b>External Policy</b> <input type="checkbox"/> <b>Internal Policy</b>	
<b>Original Date:</b> 11/13/2019 (MCCP2028) <b>Effective Date:</b> 07/01/2020 (MCCP2028)		<b>Next Review Date:</b> 06/11/2026 <b>Last Review Date:</b> 06/11/2025	
<b>Applies to:</b>	<input type="checkbox"/> <b>Employees</b>	<input checked="" type="checkbox"/> <b>Medi-Cal</b>	<input checked="" type="checkbox"/> <b>Partnership Advantage</b>

is mailed to the Medi-Cal eligible beneficiary within two (2) business days of the decision. Please refer to policy MCUP3037 Appeals of Utilization Management/ Pharmacy Decisions for further information on the appeals process.

- E. Behavioral Health Clinical Director Residential SUD TAR Reviews
1. The Behavioral Health Clinical Director may be consulted by UM nurses to review any case for which their expertise may be necessary, as determined by UM nurses upon review of case materials from provider.
  2. The Behavioral Health Clinical Director will review for medical necessity any request for residential SUD treatment episode exceeding 3 episodes in the prior 365 days.
  3. The Behavioral Health Clinical Director will review for medical necessity any request for extension of residential SUD treatment exceeding 90 contiguous days (adults), or 45 days (adolescents).

## VII. REFERENCES:

- A. Department of Health Care Services (DHCS) Intergovernmental Agreement for Drug Medi-Cal Organized Delivery System (DMC-ODS) Services
- B. [Drug Medi-Cal Organized Delivery System \(DMC-ODS\) webpage](#)
- C. Title 42 Code of Federal Regulations (CFR) Section [438.210](#) (a)(4)
- D. Title 22 California Code of Regulations (CCR) Sections [51303](#) and [51340.1](#)
- E. Department of Health Care Services (DHCS) Behavioral Health Information Notice [\(BHIN\) No: 21-021 Drug Medi-Cal Organized Delivery System – Updated Policy on Residential Treatment Limitations](#) (May 14, 2021)
- F. InterQual® Behavioral Health Criteria
- G. National Committee for Quality Assurance (NCQA) Guidelines (Effective July 1, 2025) UM 1 Program Structure Element A, UM 2 Clinical Criteria for UM Decisions Element A and UM 4 Appropriate Professionals Element A
- H. DHCS All Plan Letter [\(APL\) 21-011](#) Grievance and Appeals Requirements, Notice and “Your Rights” Templates (08/31/2021)
- I. DHCS "CalAIM Dual Eligible Special Needs Plan (D-SNP) Policy Guide - Contract Year 2026" (Re-release date 12/20/2024) <https://www.dhcs.ca.gov/provgovpart/Documents/CY2026-D-SNP-Policy-Guide.pdf>

## VIII. DISTRIBUTION:

- A. Partnership Department Directors
- B. Partnership Provider Manual

## IX. POSITION RESPONSIBLE FOR IMPLEMENTING PROCEDURE: Behavioral Health Clinical Director

## X. REVISION DATES:

MPUP3144 (06/11/2025)  
06/11/25

Medi-Cal MCUP3144 (05/11/2022):  
06/14/23; 06/12/24

## PREVIOUSLY APPLIED TO:

MCCP2028  
04/08/20, 04/14/21; 09/08/2021 – 05/10/2022

\*\*\*\*\*

<b>Policy/Procedure Number: MPUP3144 (previously MCUP3144, MCCP2028)</b>		<b>Lead Department: Health Services Business Unit: Utilization Management</b>	
<b>Policy/Procedure Title:</b> Residential Substance Use Disorder Treatment Authorization		<input checked="" type="checkbox"/> <b>External Policy</b> <input type="checkbox"/> <b>Internal Policy</b>	
<b>Original Date:</b> 11/13/2019 (MCCP2028) <b>Effective Date:</b> 07/01/2020 (MCCP2028)		<b>Next Review Date:</b> 06/11/2026 <b>Last Review Date:</b> 06/11/2025	
<b>Applies to:</b>	<input type="checkbox"/> <b>Employees</b>	<input checked="" type="checkbox"/> <b>Medi-Cal</b>	<input checked="" type="checkbox"/> <b>Partnership Advantage</b>

In accordance with the California Health and Safety Code, Section 1363.5, this policy was developed with involvement from actively practicing health care providers and meets these provisions:

- Consistent with sound clinical principles and processes
- Evaluated and updated at least annually
- If used as the basis of a decision to modify, delay or deny services in a specific case, the criteria will be disclosed to the provider and/or enrollee upon request

The materials provided are guidelines used by Partnership to authorize, modify or deny services for persons with similar illnesses or conditions. Specific care and treatment may vary depending on individual need and the benefits covered under Partnership.

Partnership's authorization requirements comply with the requirements for parity in mental health and substance use disorder benefits in 42 CFR 438.910.